- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01088035
Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma
February 27, 2015 updated by: Jason Fangusaro, Ann & Robert H Lurie Children's Hospital of Chicago
A Phase II Multi-Institutional Trial of Focal Radiotherapy With Concomitant Carboplatin as a Radiosensitizer and the Prospective Analysis of Survivin, an Inhibitor of Apoptosis, as a Biomarker in Children With Newly Diagnosed Non-Metastatic Ependymoma and Minimal Residual Disease Post-Operatively
This is a phase II study evaluating the feasibility of concurrent carboplatin given with focal radiation therapy in children age 12 months to < 21 years with newly diagnosed localized ependymoma who have no or minimal residual disease post-operatively (< 0.5 cm).
The hypothesis is that utilizing carboplatin as a radiosensitizer is feasible and tolerable and may improve event-free survival (EFS) and minimize local recurrences as compared to historic controls.
Following a neurosurgical resection and staging, patients who meet the eligibility criteria will receive standard fractionated radiation therapy at doses of 54 to 59.4 Gy to the primary site depending upon age.
All patients will receive 35 mg/m²/day of carboplatin prior to each fraction of radiotherapy.
Although significant neutropenia is not anticipated, G-CSF will be administered per study guidelines during radiation if neutropenia occurs.
All patients will be followed for toxicity, response (resolution of residual disease) and event-free survival (EFS).
Patients' tumor sample, blood and cerebro-spinal fluid (CSF) will also be prospectively evaluated to quantify the level of Survivin, a known inhibitor of apoptosis, via immunohistochemistry, Western Blot Analysis (in tumor tissue) and ELISA (in blood and CSF).
The feasibility of obtaining these levels prospectively and in real time will be evaluated.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
75
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Children's Memorial Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 21 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must be enrolled before treatment begins.
- Patients must be ≥ 12 months and < 22 years of age at the time of diagnosis.
- The target tumors are primary brain non-metastatic (M0) ependymomas tumors. Patients must have histologic verification of an ependymoma at diagnosis. Patients with the following world health organization (WHO) diagnoses will be eligible for this study:Ependymoma (Subtypes: cellular, papillary, clear cell and tanycytic) and Anaplastic Ependymoma
- Life expectancy of ≥ 8 weeks.
- Newly diagnosed ependymoma and must not have had any prior chemotherapy or radiotherapy.
All patients must have:
- A pre-operative MRI scan of the brain with and without contrast. NOTE: CT scans are NOT sufficient for study eligibility since radiation therapy planning and responses will be based on MRI scans only.
- Post-operative head MRI scan with and without contrast (preferably within 72 hours post-operatively).
- Spinal MRI (T-1 weighted imaging with and without gadolinium) is required within 28 days of surgery if done post-operatively and within 14 days of surgery if done pre-operatively. For posterior fossa tumors, pre-operative MRI scans are preferred because surgically induced inflammation/blood can be difficult to distinguish from tumor.
- Lumbar CSF cytology examination obtained between 7 and 31 days following surgery.
- Adequate bone marrow function, defined as:
- Peripheral absolute neutrophil count (ANC) >1500/μL
- Platelet count ≥ 100,000/μL (transfusion independent)
- Hemoglobin ≥ 10.0 gm/dl (may receive RBC transfusions)
- Adequate renal function defined as:
- Serum creatinine < 1.5 times the upper limit of normal based on the patient's age, or creatinine clearance greater than 60 ml/min/1.73 m² corrected for age and body surface area.
- Adequate liver function defined as:
- Total bilirubin <1.5 x the institutional normal
- SGOT (AST) or SGPT (ALT) <2.5 x institutional normals.
- Patients must begin chemoradiotherapy within 56 days of definitive surgery.
- All patients and/or their parents or legal guardians must sign a written informed consent
- Patients must provide assent as per local IRB guidelines (if applicable).
- Patients and/or their families must consent to the mandatory biology studies, including serum Survivin levels, CSF Survivin levels, paraffin-embedded tissue and fresh-frozen tissue when available.
- Karnofsky/Lansky scoring greater than 50.
- Corticosteroid supportive care is permissible at the clinician's discretion prior to and during chemo-radiotherapy.
- Anti-seizure medication support is permitted as necessary and at the treating physician's discretion.
Exclusion:
- Prior chemotherapy or prior radiotherapy
- Patients who are pregnant or breast feeding, or patients (male or female) not employing adequate contraception. Acceptable means of birth control include IUD, oral contraceptive, subdermal implant, a condom with a contraceptive sponge or suppository or abstinence.
- Patients who are unable to undergo MR imaging
- Patients with evidence of metastatic disease on spine MRI or CSF sampling
- Patients with post-operative residual tumor > 0.5 cm, unless a repeat surgery is performed making the residual tumor less than 1.5 cm². Note: Timing for enrollment and initiation of therapy will begin after second surgery if a repeat surgery is performed.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Carboplatin
|
Patients will receive daily carboplatin as a radiation sensitizer prior to radiation each day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure the EFS of newly diagnosed non-metastatic ependymoma patients treated with a combination of daily carboplatin as a radiosensitizer and conformal radiotherapy.
Time Frame: 3 years
|
3 years
|
|
Explore the tolerability, feasibility and toxicities associated with daily carboplatin as a radiosensitizer in patients with newly diagnosed non-metastatic ependymoma receiving focal fractionated radiotherapy.
Time Frame: 1 year
|
Tolerability and toxicity will be measured by documenting the toxicities associated with this treatment using the current CTCAE version 4.0.
The feasibility of this therapy will be measured by observing the ability to finish therapy without delays and the ability to receive daily carboplatin and radiation in the time alloted by the study (within 4 hours) on a daily basis.
Delays in therapy will be documented in an effort to define both tolerability and feasibility.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Explore the overall survival (OS) in patients with newly diagnosed non-metastatic ependymoma treated with this regimen.
Time Frame: 3 years
|
3 years
|
Evaluate the feasibility of quantifying Survivin expression in primary ependymoma tumor, blood and CSF samples in a prospective fashion.
Time Frame: 6 months
|
6 months
|
Explore trends or relationships between Survivin expression (in tumor, blood and CSF samples) and tumor histology.
Time Frame: 3 years
|
3 years
|
Explore trends or relationships between Survivin expression (in tumor, blood and CSF samples) and patient responses.
Time Frame: 3 years
|
3 years
|
Explore trends or relationships between Survivin expression (in tumor, blood and CSF samples) and survival outcomes.
Time Frame: 3 years
|
3 years
|
Explore trends or relationships between Survivin expression (in tumor, blood and CSF samples) tumor recurrences.
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Jason Fangusaro, MD, Ann & Robert H Lurie Children's Hospital of Chicago
- Principal Investigator: Rachel Altura, MD, Brown University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Primary Completion (Actual)
January 1, 2015
Study Completion (Anticipated)
April 1, 2015
Study Registration Dates
First Submitted
March 16, 2010
First Submitted That Met QC Criteria
March 16, 2010
First Posted (Estimate)
March 17, 2010
Study Record Updates
Last Update Posted (Estimate)
March 2, 2015
Last Update Submitted That Met QC Criteria
February 27, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CMH 09C4
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ependymoma
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingEpendymoma | Anaplastic Ependymoma | Clear Cell Ependymoma | Brain Ependymoma | Cellular Ependymoma | Papillary EpendymomaUnited States, Canada, Australia, New Zealand
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Infratentorial Ependymoma | Childhood Supratentorial Ependymoma | Newly Diagnosed Childhood EpendymomaUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoNorthwestern UniversityTerminatedGlioblastoma Multiforme | Ependymoma | Anaplastic Ependymoma | Astrocytoma, Grade III | Clear Cell EpendymomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingEpendymoma | Anaplastic EpendymomaUnited States
-
National Cancer Institute (NCI)TerminatedEpendymoma | Anaplastic Ependymoma | EpendymomasUnited States
-
National Cancer Institute (NCI)CompletedEpendymoma | Anaplastic EpendymomaUnited States
-
National Cancer Institute (NCI)TerminatedAdult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Ependymoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Myxopapillary Ependymoma | Adult Oligodendroglioma | Adult Pilocytic... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingAdult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Ependymoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Myxopapillary Ependymoma | Adult Oligodendroglioma | Adult Pilocytic... and other conditionsUnited States
-
Rush University Medical CenterAxelar ABTerminatedGlioblastoma | Gliosarcoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Ependymoma | Anaplastic OligodendrogliomaUnited States
-
Centre Leon BerardRecruitingChildhood EpendymomaItaly, Denmark, France, Czechia, Sweden, Germany, Slovenia, United Kingdom, Austria, Belgium, Ireland, Netherlands, Norway, Spain, Switzerland
Clinical Trials on Carboplatin
-
Eisai Inc.CompletedCancerUnited States, Austria, India
-
Samyang Biopharmaceuticals CorporationCompleted
-
NHS Greater Glasgow and ClydeCompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited Kingdom, Australia, New Zealand
-
Duke UniversityCompletedBrain and Central Nervous System TumorsUnited States, Canada
-
National Cancer Institute (NCI)CompletedBreast Cancer | Ovarian CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Eli Lilly and CompanyCompletedLung NeoplasmsUnited States
-
National Cancer Institute (NCI)Children's Oncology GroupCompletedBrain and Central Nervous System TumorsUnited States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
-
All India Institute of Medical Sciences, New DelhiCouncil of Scientific and Industrial Research, IndiaUnknownIntraocular RetinoblastomaIndia
-
MEI Pharma, Inc.CompletedPeritoneal Neoplasms | Ovarian Cancer | Fallopian Tube CancerUnited States, Spain, Belgium, United Kingdom, Australia, Italy, Poland